期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人催乳素受体拮抗剂G129R-hPRL在乳腺肿瘤治疗中的研究进展

Advances in the Research of Human Prolactin Receptor Antagonists G129R-hPRL in Breast Cancer Therapy
原文传递
导出
摘要 目的介绍特异性人催乳素(PRL)受体拮抗剂G129R-hPRL在乳腺肿瘤治疗中的研究进展。方法查阅近年来国内外相关文献进行总结和归纳,对G129R-hPRL的功能、作用机制、优缺点、改进措施以及在乳腺肿瘤治疗中的应用和今后的发展方向进行综述。结果 G129R-hPRL通过竞争性拮抗内源性PRL的作用进而抑制乳腺癌细胞增殖,介导癌细胞凋亡,从而发挥其抗肿瘤效应。以G129R-hPRL为基础的多功能融合蛋白、以及与其他抗肿瘤成分联合应用显示出更强的肿瘤抑制效力。结论 G129R-hPRL有望成为一种治疗以及预防乳腺癌的理想药物。 OBJECTIVE To introduce the progress of specific human prolactin receptor antagonist G129R-hPRL in breast cancer therapy research.METHODS Review the function,mechanism,advantages and disadvantages,improvements,the application and the prospect of the prolactin receptor antagonist G129R-hPRL in therapy of breast tumor through searching and summarizing relevant literatures.RESULTS G129R-hPRL can inhibit proliferation,mediate apoptosis of breast cancer cell and play the role of anti-breast cancer by competitively antagonize endogenous prolactin.G129R-hPRL-based multi-functional fusion protein,as well as combination G129R-hPRL with other anti-tumor component also shows a stronger tumor suppressor effect.CONCLUSION G129R-hPRL is expected to be an ideal drug in treatment and prevention of breast cancer.
作者 顾丽 张君 苏燕
机构地区 内蒙古科技大学包头医学院病原生物学教研室 内蒙古科技大学包头医学院生物化学与分子生物学教研室
出处 《中国现代应用药学》 CAS CSCD 北大核心 2011年第1期30-34,共5页 Chinese Journal of Modern Applied Pharmacy
基金 内蒙古自治区自然科学基金项目(200711020913)
关键词 催乳素 催乳素受体拮抗剂 G129R-hPRL 乳腺肿瘤 prolactin prolactin receptor antagonist G129R-hPRL breast tumor
分类号 R9-13 [医药卫生—药学] R962.1 [医药卫生—药理学]
  • 相关文献

参考文献22

  • 1TALLET E, ROUET V, JOMAIN J B, et al. Rational design of competitive prolactin/growth hormone receptor antagonists [J]. J Mammary Gland Biol Neoplasia,2008,13(1): 105-117.
  • 2LANGENHEIM J F, TAN D, WALKER A M, et al. Two wrongs can make a right: Dimers of prolactin and growth hormone receptor antagonists behave as agonists [J]. Mol Endocrinol, 2006, 20(3): 661-674.
  • 3BROUTIN I, JOMAIN J B, TALLET E, et al. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2 [J]. J Biol Chem, 2010, 285(11): 8422-8433.
  • 4SWAMINATHAN G, VARGHESE B, FUCHS S Y. Regulation of prolactin receptor levels and activity in breast cancer [J]. Mammary Gland Biol Neoplasia, 2008, 13(1): 81-91.
  • 5CLEVEN(3ER C V, ZHENG J, JABLONSKI E M, et al. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics [J]. Mammary Gland Biol Neoplasia, 2008, 13(1): 147-156.
  • 6TWOROGER S S, HANKINSON S E. Prolactin and breast cancer risk [J]. Cancer Lett, 2006, 243(2): 160-169.
  • 7TWOROGER S S, SLUSS P, HANKINSON S E. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women [J]. Cancer Res, 2006, 66(4): 2476-2482.
  • 8OAKES S R, ROBERTSON F G, KENCH J G. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions [J]. Oncogene, 2007, 26(4): 543-553.
  • 9CHEN W Y, RAMAMOORTHY P, CHEN N, et al. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis [J]. Clin Cancer Res, 1999, 5(11): 3583-3593.
  • 10CHEN N Y, HOLLE L, LI W, et al. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R [J]. Int J Oncol, 2002, 20(4): 813-818.

二级参考文献16

  • 1TALLET E, ROUET V, JOMAIN JB, et al. Rational design of competitive prolactin/growth hormone receptor antagonists [ J ]. J Mammary Gland Biol Neoplasia, 2008,13 ( 1 ) : 105 - 117.
  • 2CLEVENGER CV, ZHENG J, JABLONSKI EM, et al. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics [ J ]. J Mammary Gland Biol Neoplasia ,2008,13 ( 1 ) : 147 - 156.
  • 3SWAMINATHAN G, VARGHESE B, FUCHS SY. Regulation of prolactin receptor levels and activity in breast cancer [ J ]. J Mammary Gland Biol Neoplasia ,2008,13 (1) :81 - 91.
  • 4GOFFIN V, BERNICHTEIN S, TOURAINE P, et al. Development and potential clinical uses of human prolactin receptor antagonists [ J ]. Endocr Rev ,2005 ,26 ( 3 ) :400 - 422.
  • 5HUANG K, UEDA E, CHEN Y, et al. Paradigm-shifters: phosphorylated prolactin and short prolactin receptors[J]. J Mammary Gland Biol Neoplasia ,2008,13 ( 1 ) :69 - 79.
  • 6WALKER AM. S179D prolactin: antagonistic agony! [J]. Mol Cell Endocrinol, 2007,276 ( 1-2 ) : 1 - 9.
  • 7GUZMAN EA, LANGOWSKI JL, DE GUZMAN A, et al. S179D prolactin diminishes the effects of UV light on epidermal gamma delta T cells[J]. Mol Cell Endocrinol, 2008,280(1-2) : 6 -12.
  • 8NEPHEW BC, AMICO J, CAI HM, et al. Intraeerebroventricular administration of the prolactin (PRL) receptor antagonist, S179D PRL, disrupts parturition in rats[J]. Reproduction,2007,134(1) :155 - 160.
  • 9GUZMAN EA, CHEN YH, LANGOWSKI JL, et al. Abrogation of delayed type hypersensitivity response to Candida albicans produced by a molecular mimic of phosphorylated prolactin [ J ]. J Neuroimmunol, 2005,170 (1-2) : 31 - 40.
  • 10UEDA E, OZERDEM U, CHEN YH, et al. A molecular mimic demonstrates that phosphorylated human prolactin is a potent antiangiogenic hormone [ J ]. Endocr Relat Cancer, 2006,13 ( 1 ) : 95 -111.

共引文献2

中国现代应用药学
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部